Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 70, Issue 9, 2011, Pages 788-798

  Tremblay, Cyntia ^a   St Amour, Isabelle ^a   Schneider, Julie ^b   Bennett, David A ^b   Calon, Frédéric ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Amyloid; Human; Immunoblot; Mild cognitive impairment; Tau; TDP 43

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAR DNA BINDING PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AMYLOID PLAQUE; BIOACCUMULATION; BRAIN LEVEL; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; MALE; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; BRAIN; COGNITION DISORDERS; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; PEPTIDE FRAGMENTS; POSTMORTEM CHANGES;

EID: 80052185880     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31822c62cf     Document Type: Review

References (66)

1. Johnson BS, Snead D, Lee JJ, et al. TDP-43 is intrinsically aggregationprone and ALS-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 2009;284:20329-39
2. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319:1668-72 (Pubitemid 351432505)
3. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-33 (Pubitemid 44547757)
4. Mackenzie IRA, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61:427-34 (Pubitemid 46878770)
5. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602-11 (Pubitemid 44708852)
6. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update. Acta Neuropathol 2010;119:1-4
7. Pesiridis GS, Lee VMY, Trojanowski JQ. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 2009;18:R156-62
8. Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 2010;19:R46-64
9. Neumann M. Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci 2009;10:232-46
10. Geser F, Martinez-Lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009; 66:180-89
11. Buratti E, Baralle FE. The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet 2009;66:1-34
12. Geser F, Martinez-Lage M, Kwong LK, et al. Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: The TDP-43 diseases. J Neurol 2009;256:1205-14
13. Buratti E, De Conti L, Stuani C, et al. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J 2010;277:2268-81
14. Igaz LM, Kwong LK, Chen-Plotkin A, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 poteinopathies. J Biol Chem 2009;284:8516-24
15. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65(Suppl 1):S3-9
16. Cairns NJ, Neumann M, Bigio EH, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 2007;171:227-40 (Pubitemid 47342406)
17. Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA 2009;106: 7607-12
18. Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008;64:60-70
19. Hu WT, Josephs KA, Knopman DS, et al. Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 2008;116:215-20
20. Kadokura A, Yamazaki T, Lemere CA, et al. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: Their relation to AD common pathology. Neuropathology 2009;29:566-73
21. Uryu K, Nakashima-Yasuda H, Forman MS, et al. Concomitant TARDNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008;67:555-64 (Pubitemid 351787082)
22. Arai T, Mackenzie IRA, Hasegawa M, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 2009;117:125-36
23. Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007;61: 435-45 (Pubitemid 46878771)
24. Higashi S, Iseki E, Yamamoto R, et al. Concurrence of TDP-43, tau and [alpha]-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 2007;1184:284-94 (Pubitemid 350160566)
25. Josephs KA, Whitwell JL, Knopman DS, et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008;70:1850
26. Rauramaa T, Pikkarainen M, Englund E, et al. TAR-DNA binding protein-43 and alterations in the hippocampus. J Neural Transm 2011; 118:683-89
27. King A, Sweeney F, Bodi I, et al. Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease. Neuropathology 2010;30:408-19
28. Bigio EH, Mishra M, Hatanpaa KJ, et al. TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol 2010;120:43-54
29. Rohn TT. Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease. Brain Res 2008;1228:189-98
30. Lippa CF, Rosso AL, Stutzbach LD, et al. Transactive response DNAbinding protein 43 burden in familial Alzheimer disease and Down syndrome. Arch Neurol 2009;66:1483-88
31. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: Ten years later. Arch Neurol 2009;66:1447-55
32. Tremblay C, Pilote M, Phivilay A, et al. Biochemical characterization of AA and tau pathologies in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2007;12:377-90
33. Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005;64:834-41 (Pubitemid 40316322)
34. Markesbery WR. Neuropathologic alterations in mild cognitive impairment: A review. J Alzheimers Dis 2010;19:221-28
35. Imhof A, Kovari E, von Gunten A, et al. Morphological substrates of cognitive decline in nonagenarians and centenarians: A new paradigm? J Neurol Sci 2007;257:72-79 (Pubitemid 46876646)
36. Haneuse S, Larson E, Walker R, et al. Neuropathology-based risk scoring for dementia diagnosis in the elderly. J Alzheimers Dis 2009;17:875-85
37. Jellinger KA. Criteria for the neuropathological diagnosis of dementing disorders: Routes out of the swamp? Acta Neuropathol 2009;117:101-10
38. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol 2009;68:1-14
39. Zhang HX, Tanji K, Mori F, et al. Epitope mapping of 2E2-D3, a monoclonal antibody directed against human TDP-43. Neurosci Lett 2008;434: 170-74
40. Bennett DA. Postmortem indices linking risk factors to cognition: Results from the Religious Order Study and the Memory and Aging Project. Alzheimer Dis Assoc Disord 2006;20:S63-68 (Pubitemid 44265853)
41. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205 (Pubitemid 34779177)
42. Bennett DA, Schneider JA, Buchman AS, et al. The Rush Memory and Aging Project: Study design and baseline characteristics of the study cohort. Neuroepidemiology 2005;25:163-75 (Pubitemid 41540657)
43. Wilson RS, Leurgans SE, Boyle PA, et al. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol 2011;68: 351-56
44. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
45. Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 2003;60:246-52 (Pubitemid 36152017)
46. Wilson RS, Beckett LA, Barnes LL, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002;17: 179-93 (Pubitemid 34568635)
47. Bourasset F, Ouellet M, Tremblay C, et al. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology 2009;56:808-13
48. Zhang YJ, Gendron TF, Xu YF, et al. Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol Neurodegener 2010;5:33
49. Forman MS, Mufson EJ, Leurgans S, et al. Cortical biochemistry in MCI and Alzheimer disease: Lack of correlation with clinical diagnosis. Neurology 2007;68:757-63 (Pubitemid 46667901)
50. Jellinger KA, Attems J. Prevalence of dementia disorders in the oldestold: An autopsy study. Acta Neuropathol 2010;119:421-33
51. Nelson PT, Kukull WA, Frosch MP. Thinking outside the box: Alzheimertype neuropathology that does not map directly onto current consensus recommendations. J Neuropathol Exp Neurol 2010;69:449-54
52. Julien C, Tremblay C, Bendjelloul F, et al. Decreased drebrin mRNA expression in Alzheimer disease: Correlation with tau pathology. J Neurosci Res 2008;86:2292-302
53. Bennett DA, Schneider JA, Wilson RS, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004;61:378-84 (Pubitemid 38327357)
54. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid {beta}-peptide in the brain and cognitive decline. JAMA 2000;283:1571-77 (Pubitemid 30161512)
55. Rutherford NJ, Zhang YJ, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 2008;4:e1000193
56. Inukai Y, Nonaka T, Arai T, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett 2008;582:2899-904
57. Arai T, Hasegawa M, Nonoka T, et al. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology 2010;30:170-81
58. Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 2009;117:137-49
59. Gamblin TC, Chen F, Zambrano A, et al. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA 2003;100:10032-37 (Pubitemid 37087063)
60. Gervais FG, Xu D, Robertson GS, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-[beta] precursor protein and amyloidogenic A [beta] peptide formation. Cell 1999;97:395-406
61. Rissman RA, Poon WW, Blurton-Jones M, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004;114:121-30 (Pubitemid 39071651)
62. Rohn TT, Head E, Su JH, et al. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 2001;158:189-98 (Pubitemid 32096484)
63. Yang F, Sun X, Beech W, et al. Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am J Pathol 1998;152:379-89 (Pubitemid 28106384)
64. LeBlanc AC. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res 2005;2:389-402
65. Dormann D, Capell A, Carlson AM, et al. Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem 2009;110:1082-94
66. Sephton CF, Cenik C, Kucukural A, et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem 2011;286:1204-15